Entera Bio ENTX
NASDAQ ENTX
$3.02 +0.00 (+0.00%)
As of: Oct 21, 2026 · 11:37 AM EDT

Entera Bio (ENTX) Current Deferred Revenue (2020 - 2021)

Updated

Entera Bio (ENTX) reported Current Deferred Revenue of $15,000 for Q4 2021, down 90.5% from $158,000 a year earlier.

Analysis

Entera Bio (ENTX) Current Deferred Revenue (2020 - 2021) Analysis & Trends

  • By year, Current Deferred Revenue came in at $158,000 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn
10 Entera Bio 152.36 Mn 121.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 15,000.00
Dec 31, 2020 158,000.00
API Access

Entera Bio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ENTX&period=max&api_key=YOUR_API_KEY